Pentwater Capital Management LP purchased a new stake in PAREXEL International Corporation (NASDAQ:PRXL) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 200,000 shares of the medical research company’s stock, valued at approximately $17,382,000. Pentwater Capital Management LP owned about 0.39% of PAREXEL International Corporation as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio boosted its holdings in PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after acquiring an additional 73 shares during the last quarter. Invictus RG bought a new position in PAREXEL International Corporation in the first quarter valued at about $158,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in PAREXEL International Corporation by 10.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock valued at $173,000 after acquiring an additional 180 shares during the last quarter. Advisor Group Inc. boosted its holdings in PAREXEL International Corporation by 75.1% in the second quarter. Advisor Group Inc. now owns 2,000 shares of the medical research company’s stock valued at $173,000 after acquiring an additional 858 shares during the last quarter. Finally, BlueCrest Capital Management Ltd bought a new position in PAREXEL International Corporation in the first quarter valued at about $202,000. Institutional investors and hedge funds own 87.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/05/pentwater-capital-management-lp-purchases-new-holdings-in-parexel-international-corporation-prxl.html.

PAREXEL International Corporation (NASDAQ:PRXL) traded down 0.02% during midday trading on Thursday, hitting $88.08. The stock had a trading volume of 7,021,106 shares. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of 42.76 and a beta of 0.77. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $88.10. The company’s 50 day moving average price is $87.74 and its 200-day moving average price is $78.14.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to the consensus estimate of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same period in the previous year, the business earned $0.94 EPS. Equities analysts anticipate that PAREXEL International Corporation will post $3.90 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on PRXL shares. BidaskClub cut PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a report on Tuesday, August 8th. Jefferies Group LLC reiterated a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research note on Tuesday, June 20th. Finally, Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 target price on the stock. in a research note on Tuesday, June 20th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $75.92.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.